Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on January 20, 2015. The report covers events occurring on this date, specifically the announcement of clinical study results presented at the 2015 Gastrointestinal Cancer Symposium (ASCO GI) in San Francisco, CA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a scientific milestone rather than financial performance.
Material Changes
The material event reported is the presentation of data demonstrating the efficacy of the Company's Precision Cancer MonitoringSM platform. The results indicate the platform's ability to detect and quantitate KRAS mutations at diagnosis and longitudinally in cell-free DNA (cfDNA) from colorectal and pancreatic cancer patients.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future financial outlook, or a discussion of risks and contingencies. The primary focus is the dissemination of clinical data via a press release furnished as Exhibit 99.1.
Investor Verification Checklist
- Verify the registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Review the attached press release (Exhibit 99.1) for detailed clinical data on KRAS mutation detection.
- Confirm the specific patient cohorts and statistical significance of the colorectal and pancreatic cancer study results.
- Check subsequent filings for any financial impact or strategic shifts resulting from these clinical findings.